All In Biotech

Drug Trial Radar · NCT07059377

Semaglutide for Smoking Cessation in Patients With Diabetes

Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Dec 2026

Study completion Jul 2027

Sponsor

Lead sponsor
Ottawa Heart Institute Research CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

Conditions

  • Diabetes Mellitus, Type 2
  • Nicotine Addiction
  • Tobacco Dependence

Interventions

  • SemaglutideDrug

    Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks

  • Nicotine replacementDrug

    Nicotine patch plus short-acting NRT gum or lozenge

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Project successTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.